Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A53523 | Pages: 161 | Charts: 51 | Tables: 68 |
Middle East Blood Plasma Derivative Market Insight 2022-2032
The Middle East blood plasma derivative market size was valued at $ 1,115.16 Million in 2021, and is projected to reach $ 3,037.01 Million by 2032, registering a CAGR of 9.4% from 2022 to 2032. The blood cells are suspended in the fluid component of blood known as blood plasma. In addition, red blood cells, white blood cells, and platelets are suspended in the clear liquid blood component known as blood plasma. It includes dissolved proteins, clotting factors, hormones, and electrolytes (albumins, globulins, and fibrinogen). Plasma regulates blood pressure and helps the body's pH balance by facilitating the exchange of salt and potassium, two essential minerals.
[COVIDIMPACTSTATEMENT]
Plasma derivatives are goods created from human plasma utilizing plasma fractionation techniques. These derivatives include albumin, factor VIII and IX, anti-inhibitor coagulation complex, and immunoglobulins such as Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III. Application of blood plasma derivative are HIV, hemophilia, immunodeficiency diseases, bleeding disorders, liver conditions, viral disease, and others. End users of blood plasma derivative are hospitals, clinics, and transfusion centers.
“The middle east blood plasma derivative market was slightly positive during the lockdown period owing to increase in the usage of plasma therapy during COVID-19 is anticipated to fuel the market growth”
Historical Overview
The market was analyzed qualitatively and quantitatively from 2021-2032. The Middle east blood plasma derivative market grew at a CAGR of around 9.4% during 2022-2032. Most of the growth during this period was derived from the Rest of Middle East owing to the rise in the number of key players who manufactures blood plasma derivative product, rising disposable incomes, as well as well-established presence of domestic companies in the region.
Market Dynamics
Growth of the global Middle east blood plasma derivative market is majorly driven by rise in prevalence of life-threatening diseases such as immunodeficient diseases, bleeding disorders like hemophilia and rise in number of blood donations. Moreover, increase in number of geriatric populations who is more susceptible to immunodeficiency diseases are anticipated to drive the growth of middle east blood plasma derivative market. Increase in the number of patients with life threatening diseases, such as hemophilia, immunodeficiency diseases, and many more, in the past few decades has enforced manufacturers to develop blood plasma derivatives. Hemophilia is a condition caused due to the human body's inability to produce certain proteins (factor VIII or factor IX), which are required for blood clotting. Thus, physicians administer blood plasma derivatives for the treatment purpose in hemophilia. Thus, increase in prevalence of hemophilia fuels the demand for plasma derivatives by hospitals, clinics, and transfusion centers.
This factor is anticipated to boost the growth of Middle East blood plasma derivatives market. For instance, in 2020, according to the data shared by World Federation of Hemophilia, in Saudi Arabia, 1,067 population is suffering from hemophilia. As per the same source Saudi Arabia uses 148,120,00 units Factor IIV for treatment of hemophilia in 2020. Furthermore, immunoglobulins are used for treating patients with immunodeficiency disorders by maintaining adequate levels of specific antibodies. Therefore, high prevalence of these diseases could trigger the demand for plasma derivatives products. Moreover, other applications of plasma derivatives in other immunodeficiency disorders, von Willebrand's disease (vWD), hereditary angioedema (HAE), Rh incompatibility condition, and Kawasaki Disease, help its use in the biopharmaceutical industry.
Moreover, the geriatric population across the Middle East has significantly grown in the past few years. They are vulnerable to various life-threatening disorders such as hemophilia and immunodeficiency disorders. Thus, increase in number of geriatric populations is anticipated to drive the growth of Middle East blood plasma derivative market. For instance, according to data share by The World Bank, in 2021, geriatric population in United Arab Emirates (UAE) reached 144,722. It has increased by approximately 40% from 2010. The geriatric population in the UAE was 58,618 in 2010.
In addition, convalescent plasma and hyperimmune globulin are obtained from individuals who have recovered from an infection and have generated an immune response against the infecting pathogen. Neutralizing antibodies are thought to be the main active component. Convalescent plasma and/or hyperimmune globulin have been used as a means of providing passive immunity in several notable viral outbreaks. Early in the coronavirus disease 2019 (COVID-19) pandemic, convalescent plasma was collected by major blood centers for treatment of COVID-19. Thus, rise in prevalence of COVID-19 is anticipated to drive the growth of blood plasma derivative market.
According to, National Library of Medicine, in Israel, from April 2020 to January 2021, 4020 volunteer donors donated 5221 CCP units and 837 (20.8%) donors donated more than once. Thus, this factor is anticipated to drive the growth of Middle East blood plasma derivative market.
Increase in awareness among the people regarding usefulness of blood donation and plasma donation cause rise in the usage of plasma derivatives by physicians for treatment of hemophilia and immunodeficiency disorders.
Thus, this factor is anticipated to drive the growth of blood plasma derivative market. For instance, according to the report shared by Department of health Abu Dhabi, in 2022, there were about 25,600 blood donors in Abu Dhabi, who contributed to providing 44,000 blood units to patients and injured people since the beginning of the year. Over the past five years, around 200,000 donors contributed to improving and saving the lives of countless patients by donating 400,000 blood units across the emirate. Thus, this factor is anticipated to drive the growth of Middle East blood plasma derivatives market.
In addition, rise in the expenditure by government to develop healthcare infrastructure is anticipated to drive the growth of the market. For instance, in April 2021, according to the report shared by The Saudi Authority for Industrial Cities and Technology Zones (MODON), a government organization created by the Government of Saudi Arabia, it was reported that, MODON has leased land north of Riyadh to develop a plant to make blood plasma derivatives for a cost of $80 million.
However, Side effects associated with plasma derivatives therapy is attributes to hamper the growth of blood plasma derivatives market. Transfusion of plasma can lead to adverse reactions or events. Immune-mediated reactions are most common--these include allergic and anaphylactic reactions, transfusion-related acute lung injury (TRALI) and hemolysis. They can range in severity from mild to fatal. Fluid overload and citrate toxicity can occur after rapid or massive transfusion. Thus, this factor is anticipated to hinder the growth of blood plasma derivatives.
COVID-19 Impact on Middle East Blood Plasma Derivative Market
The COVID-19 outbreak is anticipated to have a positive impact on the growth of the middle east blood plasma derivative market. Plasma from patients that have overcome COVID-19 infection, referred to as convalescent plasma, is a treatment option with considerable background in viral diseases such as severe acute respiratory syndrome (SARS), and Middle East Respiratory Syndrome (MERS). Thus, during pandemic rise in the usage of plasma derivatives for treatment of COVID-19 is anticipated to have positive impact on the middle east blood plasma derivative market. Moreover, rise in the number of blood donation and plasma donation activity during COVID-19 is anticipated to drive the growth of market. Rise in awareness among the people regarding usefulness of blood and plasma donation and increased blood donation activity boosts the market growth. (COVID-19) pandemic, convalescent plasma was collected by major blood centers for treatment of COVID-19.
On the other hand, post the pandemic, increase in number of research activities and rise in awareness among the people regarding blood and plasma donation is attributed to have positive impact on the Middle East blood plasma derivative market.
Segmental Overview
The Middle East blood plasma derivative market is segmented by type, application, end user and country. By type, the market is segmented into albumin, factor VII, Factor IX concentrate, anti-coagulation factor, Rh immunoglobulin, others. By application the market is divided into immunodeficiency diseases, bleeding disorders, liver conditions, and others. By end user, the market is segmented into hospitals, clinics, and transfusion centers.
[TYPEGRAPH]
By Type: By type, the market is segmented into albumin, factor VII, Factor IX concentrate, anti-coagulation factor, Rh immunoglobulin, others. The others segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to effectiveness of different blood plasma derivative for treatment of immunodeficiency diseases, infectious diseases, and viral diseases and rise in the number of product launch and product approvals for different plasma derivative products.
[APPLICATIONGRAPH]
By Application: By application, the market is segmented into immunodeficiency diseases, bleeding disorders, liver conditions, and others. The bleeding disorder segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to rise in application of blood plasma derivatives for treatment of hemophilia and increase in prevalence of hemophilia due to different risk factors such as genetic history, medical conditions, procedures, or medicines can cause bleeding disorders
[ENDUSERGRAPH]
By end user: By end user, the market is divided into hospitals, clinics, and transfusion centers. The hospitals segment dominated the market in 2021 and is expected to continue this trend during the forecast period, owing to rise in number of hospitals, increase in expenditure by hospitals for development of healthcare sector and rise in the awareness among population regarding availability of treatment for different immunodeficiency and bleeding disorders.
[COUNTRYGRAPH]
Rest of middle east blood plasma derivative market is expected to grow during the forecast period owing to, Rise in the prevalence of immunodeficiency disorders and increase in application of immunoglobulins for treatment purpose is anticipated to drive the growth of blood plasma derivatives market. Moreover, rise in the number of product launch and product approvals for different immunoglobulin products is attributes to boost the growth of blood plasma derivative market. In addition, increase in the number of blood donation and rise in awareness among people regarding blood donation drives the market growth. In addition, increase in geriatric population and improved production of immunoglobulins on account of the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) drive the market.
Competition Analysis
Some of the major companies that operate in the Middle east blood plasma derivative market include Bayer AG, Biotest AG, CSL Limited., Fusion Healthcare Pvt. Ltd., Grifols, S.A., Kedrion Biopharma, Inc., LFB S.A (LFB) is a bio-pharmaceutical group., Octapharma AG., Sanofi, and Takeda Pharmaceutical Co., Ltd.
Some examples of research activities in the market
For instance, according to the Research paper shared by The Lancet, in 2020, the research activity in conducted by physicians in Israel. The aim of the study was to describe the clinical outcome associated with convalescent plasma (CP) transfusion for patients with moderate and severe COVID-19 infection. The ethics committee of the Israel Ministry of Health approved the study.
Key Benefits For Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Increase in the prevalence of life-threatening diseases
3.3.1.2.Rise in the number of geriatric populations
3.3.1.3.Rise in prevalence of COVID-19
3.3.2.Restraint
3.3.2.1.Side effects associated with blood plasma derivatives
3.3.3.Opportunity
3.3.3.1.Increase in the awareness regarding blood and plasma donation
3.4.Impact analysis
3.5.Total units of blood donated by country, 2021
3.6.Impact analysis of COVID-19 on the Middle East blood plasma derivative market
CHAPTER 4:MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Albumin
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market analysis, by country
4.3.Factor VII
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market analysis, by country
4.4.Factor IX Concentrate
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market analysis, by country
4.5.Anti-Coagulation Factor
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market analysis, by country
4.6.Rh Immunoglobulin
4.6.1.Market analysis, by country
4.7.Others
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market analysis, by country
CHAPTER 5:MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Immunodeficiency Diseases
5.2.1.Key market trends, growth factors, and opportunities
5.2.1.1.HIV
5.2.1.1.1.Market size and forecast
5.2.1.2.Others
5.2.1.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Bleeding Disorder
5.3.1.Key market trends, growth factors, and opportunities
5.3.1.1.Hemophilia A & B
5.3.1.1.1.Market size and forecast
5.3.1.2.Others
5.3.1.2.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Liver Condition
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market analysis, by country
5.5.Others
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market analysis, by country
CHAPTER 6:MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market analysis, by country
6.3.Clinics
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market analysis, by country
6.4.Transfusion Centers
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market analysis, by country
CHAPTER 7:MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY COUNTRY
7.1.Overview
7.2.Middle East
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Middle East blood plasma derivative market, by type
7.2.3.Middle East blood plasma derivative market, by application
7.2.4.Middle East blood plasma derivative market, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.United Arab Emirates
7.2.5.1.1.United Arab Emirates blood plasma derivative market, by type
7.2.5.1.2.United Arab Emirates blood plasma derivative market, by application
7.2.5.1.3.United Arab Emirates blood plasma derivative market, by end user
7.2.5.2.Saudi Arabia
7.2.5.2.1.Saudi Arabia blood plasma derivative market, by type
7.2.5.2.2.Saudi Arabia blood plasma derivative market, by application
7.2.5.2.3.Saudi Arabia blood plasma derivative market, by end user
7.2.5.3.Oman
7.2.5.3.1.Oman blood plasma derivative market, by type
7.2.5.3.2.Oman blood plasma derivative market, by application
7.2.5.3.3.Oman blood plasma derivative market, by end user
7.2.5.4.Qatar
7.2.5.4.1.Qatar blood plasma derivative market, by type
7.2.5.4.2.Qatar blood plasma derivative market, by application
7.2.5.4.3.Qatar blood plasma derivative market, by end user
7.2.5.5.Rest of Middle East
7.2.5.5.1.Rest of Middle East blood plasma derivative market, by type
7.2.5.5.2.Rest of Middle East blood plasma derivative market, by application
7.2.5.5.3.Rest of Middle East blood plasma derivative market, by end user
CHAPTER 8:COMPETITION LANDSCAPE
8.1.Product mapping
8.2.Competitive dashboard
8.3.Competitive heat map
8.4.Top Player Positioning 2022
CHAPTER 9:COMPANY PROFILES
9.1.BAYER AG
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.2.BIOTEST AG
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.3.CSL LIMITED
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.FUSION HEALTH CARE PVT. LTD
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.5.GRIFOLS, S.A.
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.KEDRION BIOPHARMA, INC.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.7.LFB S.A
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.8.OCTAPHARMA AG
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.SANOFI
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.TAKEDA PHARMACEUTICAL LIMITED COMPANY
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
LIST OF TABLES
TABLE 01.TOTAL UNITS OF BLOOD DONATED BY COUNTRY: 2021
TABLE 02.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2021–2032 ($MILLION)
TABLE 03.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2021–2032 ($MILLION)
TABLE 04.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY IMMUNODEFICIENCY DISEASE, 2021–2032 ($MILLION)
TABLE 05.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY BLEEDING DISORDER, 2021–2032 ($MILLION)
TABLE 06.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2021–2032 ($MILLION)
TABLE 07.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2021–2032 ($MILLION)
TABLE 08.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2021–2032 ($MILLION)
TABLE 09.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2021–2032 ($MILLION)
TABLE 10.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 11.UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2022–2032 ($MILLION)
TABLE 12.UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2022–2032 ($MILLION)
TABLE 13.UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 14.SAUDI ARABIA BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2022–2032 ($MILLION)
TABLE 15.SAUDI ARABIA BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2022–2032 ($MILLION)
TABLE 16.SAUDI ARABIA BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 17.OMAN BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2022–2032 ($MILLION)
TABLE 18.OMAN BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2022–2032 ($MILLION)
TABLE 19.OMAN BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 20.QATAR BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2022–2032 ($MILLION)
TABLE 21.QATAR BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2022–2032 ($MILLION)
TABLE 22.QATAR BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 23.REST OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2022–2032 ($MILLION)
TABLE 24.REST OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2022–2032 ($MILLION)
TABLE 25.REST OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 26.BAYER: COMPANY SNAPSHOT
TABLE 27.BAYER: OPERATING SEGMENT
TABLE 28.BAYER: PRODUCT PORTFOLIO
TABLE 29.BAYER: R&D EXPENDITURE, 2019–2021
TABLE 30.BAYER: NET SALES, 2019–2021
TABLE 31.BIOTEST: COMPANY SNAPSHOT
TABLE 32.BIOTEST: OERATING SEGMENT
TABLE 33.BIOTEST: PRODUCT PORTFOLIO
TABLE 34.BAYER: NET SALES, 2019–2021
TABLE 35.CSL: COMPANY SNAPSHOT
TABLE 36.CSL: OERATING SEGMENT
TABLE 37.CSL: PRODUCT PORTFOLIO
TABLE 38.CSL: R&D EXPENDITURE, 2019–2021
TABLE 39.CSL: NET SALES, 2019–2021, 2019–2021
TABLE 40.FUSION HEALTHCARE: COMPANY SNAPSHOT
TABLE 41.FUSION HEALTHCARE: OERATING SEGMENT
TABLE 42.FUSION HEALTHCARE: PRODUCT PORTFOLIO
TABLE 43.GRIFOLS: COMPANY SNAPSHOT
TABLE 44.GRIFOLS: OERATING SEGMENT
TABLE 45.GRIFOLS: PRODUCT PORTFOLIO
TABLE 46.GRIFOLS: R&D EXPENDITURE, 2019–2021 ($ MILLION)
TABLE 47.GRIFOLS: NET SALES, 2019–2021, ($ MILLION)
TABLE 48.KEDRION: COMPANY SNAPSHOT
TABLE 49.KEDRION: OERATING SEGMENT
TABLE 50.KEDRION: PRODUCT PORTFOLIO
TABLE 51.KEDRION: NET SALES, 2019–2021, ($ MILLION)
TABLE 52.LFB: COMPANY SNAPSHOT
TABLE 53.LFB: OERATING SEGMENT
TABLE 54.LFB: PRODUCT PORTFOLIO
TABLE 55.OCTAPHARMA: COMPANY SNAPSHOT
TABLE 56.OCTAPHARMA: OERATING SEGMENT
TABLE 57.OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 58.OCTAPHARMA: NET SALES, 2019–2021, ($ MILLION)
TABLE 59.SANOFI: COMPANY SNAPSHOT
TABLE 60.SANOFI: OPERATING SEGMENT
TABLE 61.SANOFI: PRODUCT PORTFOLIO
TABLE 62.SANOFI: R&D EXPENDITURE, 2019–2021 ($ MILLION)
TABLE 63.SANOFI: R&D EXPENDITURE, 2019–2021 ($ MILLION)
TABLE 64.TAKEDA: COMPANY SNAPSHOT
TABLE 65.TAKEDA: OERATING SEGMENT
TABLE 66.TAKEDA: PRODUCT PORTFOLIO
TABLE 67.TAKEDA: R&D EXPENDITURE, 2019–2021 ($ MILLION)
TABLE 68.TAKEDA: R&D EXPENDITURE, 2020–2022 ($ MILLION)
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET SEGMENTATION
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY TYPE, 2021–2032 (%)
FIGURE 10.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR ALBUMIN, BY COUNTRY, 2021–2032 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR FACTOR VII, BY COUNTRY, 2021–2032 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR FACTOR IX CONCENTRATE, BY COUNTRY, 2021–2032 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR ANTI-COAGULATION FACTOR, BY COUNTRY, 2021–2032 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR RH IMMUNOGLOBULIN, BY COUNTRY, 2021–2032 (%)
FIGURE 15.COMPARASTIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR OTHERS, BY COUNTRY, 2021–2032 (%)
FIGURE 16.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY APPLICATION, 2021–2032 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR IMMODEFICIENCY DISEASES, BY COUNTRY, 2021–2032 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR BLEEDING DISORDER, BY COUNTRY, 2021–2032 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR LIVER DISORDER, BY COUNTRY, 2021–2032 (%)
FIGURE 20.COMPARASTIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR OTHERS, BY COUNTRY, 2021–2032 (%)
FIGURE 21.MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET, BY END USER, 2021–2032 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR HOSPITALS, BY COUNTRY, 2021–2032 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR CLINICS, BY COUNTRY, 2021–2032 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF MIDDLE EAST BLOOD PLASMA DERIVATIVE MARKET FOR TRANSFUSION CENTERS, BY COUNTRY, 2021–2032 (%)
FIGURE 25.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 26.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 27.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 28.TOP PLAYER POSITIONING 2022
FIGURE 29.BAYER: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 30.BAYER: NET SALES, 2019–2021 ($MILLION)
FIGURE 31.BAYER: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 32.BIOTEST: NET SALES, 2019–2021 ($MILLION)
FIGURE 33.BIOTEST: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 34.BIOTEST: REVENUE SHARE, BY REGION, 2021(%)
FIGURE 35.‘CSL: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 36.CSL: NET SALES, 2019–2021 ($MILLION)
FIGURE 37.CSL: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 38.GRIFOLS: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 39.GRIFOLS: NET SALES, 2019–2021 ($MILLION)
FIGURE 40.GRIFOS: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 41.GRIFOLS: REVENUE SHARE, BY REGION, 2021(%)
FIGURE 42.KEDRION: NET SALES, 2019–2021 ($MILLION)
FIGURE 43.OCTAPHARMA: NET SALES, 2019–2021 ($MILLION)
FIGURE 44.SANOFI: R&D EXPENDITURE, 2019–2021 ($MILLION)
FIGURE 45.SANOFI: NET SALES, 2019–2021 ($MILLION)
FIGURE 46.SANOFI: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 47.SANOFI: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 48.TAKEDA: R&D EXPENDITURE, 2020–2022 ($MILLION)
FIGURE 49.TAKEDA: NET SALES, 2020–2022 ($MILLION
FIGURE 50.TAKEDA: REVENUE SHARE, BY SEGMENT, 2022(%)
FIGURE 51.TAKEDA: REVENUE SHARE, BY REGION, 2022(%)